Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
ACOG 
Alpha Cognition Inc (ACOG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ACOG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.77% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 147.57M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 2.63 | 52 Weeks Range 3.75 - 11.54 | Updated Date 10/17/2025 |
52 Weeks Range 3.75 - 11.54 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -346.09% |
Management Effectiveness
Return on Assets (TTM) -38.27% | Return on Equity (TTM) -131.23% |
Valuation
Trailing PE - | Forward PE 26.88 | Enterprise Value 107876968 | Price to Sales(TTM) 32.18 |
Enterprise Value 107876968 | Price to Sales(TTM) 32.18 | ||
Enterprise Value to Revenue 23.52 | Enterprise Value to EBITDA -1.57 | Shares Outstanding 20902104 | Shares Floating 11215748 |
Shares Outstanding 20902104 | Shares Floating 11215748 | ||
Percent Insiders 10.03 | Percent Institutions 36.33 |
Upturn AI SWOT
Alpha Cognition Inc
Company Overview
History and Background
Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. Founded in 2017, the company is researching and developing formulations of naturally occurring metabolites.
Core Business Areas
- Drug Development: Focuses on developing proprietary formulations of naturally occurring metabolites for the treatment of cognitive impairment.
Leadership and Structure
The leadership team consists of senior executives with experience in pharmaceutical development and commercialization. The organizational structure is typical of a biopharmaceutical company, with research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- ALPHA-1062: A proprietary, slow-release formulation of alpha-GPC, is being developed for the treatment of mild to moderate Alzheimer's disease. No market share data is yet available as the drug is in clinical trials. Competitors include companies developing similar treatments for Alzheimer's, such as Eisai and Biogen with Leqembi.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is highly competitive, with significant unmet medical needs and substantial market opportunities. The market is driven by the aging population and increasing prevalence of cognitive impairment.
Positioning
Alpha Cognition Inc. is positioned as a developer of novel treatments for neurodegenerative diseases, focusing on proprietary formulations of known metabolites. Its competitive advantage lies in its unique formulation and delivery methods.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease therapeutics is estimated to be in the billions of dollars annually. Alpha Cognition is positioned to capture a share of this market pending successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary formulations
- Novel delivery methods
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- No currently marketed products
Opportunities
- Growing market for Alzheimer's treatments
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- Eisai (ESALY)
- Biogen (BIIB)
- Eli Lilly (LLY)
Competitive Landscape
Alpha Cognition faces intense competition from established pharmaceutical companies with greater resources and existing marketed products. Its success depends on demonstrating the efficacy and safety of its novel formulations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing investment in R&D.
Future Projections: Future growth depends on clinical trial results and regulatory approvals. Analyst estimates vary based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing clinical trials of ALPHA-1062 and exploring partnerships for commercialization.
Summary
Alpha Cognition Inc. is a high-risk, high-reward biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases. Its success hinges on the positive outcomes of its clinical trials and the ability to secure partnerships for commercialization. The lack of current revenue and strong competition pose challenges, but a successful drug approval could lead to substantial growth. Investors should be aware of the inherent volatility and uncertainty in pharmaceutical development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice and should not be used as the basis for investment decisions. The author is not a financial advisor. Investors should consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Cognition Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2024-11-12 | CEO & Director Mr. Michael E. McFadden B.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.alphacognition.com |
Full time employees - | Website https://www.alphacognition.com | ||
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.